

Korean firm Vuno partners with Mayo Clinic for AI-based precision oncology

25 April 2022 | News

Laying a foundation for Vuno's medical AI solutions to contribute and improve cancer diagnosis and treatment



South Korea-based startup Vuno has signed a research agreement with Mayo Clinic in the US. The research agreement, which was signed by Vuno's CEO Lee Yeha, allows both organizations to advance artificial intelligence (AI)-driven precision oncology solutions to deliver precision oncology care.

Through this research agreement, Vuno will establish a collaboration with Mayo Clinic to develop innovative AI and machine learning solutions for more precise diagnosis, prognosis and treatment stratification in cancer.

This collaborative agreement combines Vuno's AI R&D capabilities and Mayo Clinic's AI research, clinical expertise, resources, to develop a broad spectrum of predictive and prognostic biomarkers, for aiding therapeutic decisions that will improve the quality of cancer patient care.

The synergy of R&D expertise, resources, and multi-omics data will allow Vuno and Mayo Clinic to develop breakthrough AI and machine learning technology that can be introduced into clinical practice. This research will allow Vuno to explore the future of precision oncology and create start-to-finish AI/Machine Learning powered solutions that can determine the best therapeutic strategies for patients.